The Pure-Play Pivot
Haleon and a New Era in Consumer Healthcare
The global consumer healthcare sector reached a definitive inflexion point at the start of May 2026. The transition of major pharmaceutical conglomerates toward pure-play consumer entities is now largely complete, and the focus has shifted from demerger execution to operational excellence. Haleon PLC, following its separation from GSK and Pfizer, has entered a critical phase of its Win as One strategy. This plan aims to reconcile the agility of a fast-moving consumer goods company with the scientific rigour of its pharmaceutical heritage. This analysis reviews Haleon’s performance through the fiscal year 2025 and the first quarter of 2026, synthesising financial data and competitive signals to assess its standing as a premier global giant in the field.
